159 related articles for article (PubMed ID: 34350562)
1. Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers.
Huang Y; Qi M; Liao C; Xun J; Zou J; Huang H; Long LY; Chen J; Fan X; Chen R
Infect Dis Ther; 2021 Dec; 10(4):2323-2331. PubMed ID: 34350562
[TBL] [Abstract][Full Text] [Related]
2. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
Cao Z; Liu Y; Ma L; Lu J; Jin Y; Ren S; He Z; Shen C; Chen X
Hepatology; 2017 Oct; 66(4):1058-1066. PubMed ID: 28407271
[TBL] [Abstract][Full Text] [Related]
3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
4. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy.
Jindal A; Vyas AK; Kumar D; Kumar G; Sharma MK; Sarin SK
Hepatol Res; 2018 May; 48(6):451-458. PubMed ID: 29314573
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers.
Wu F; Lu R; Liu Y; Wang Y; Tian Y; Li Y; Li M; Wang W; Zhang X; Jia X; Dang S
Liver Int; 2021 Sep; 41(9):2032-2045. PubMed ID: 33896094
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.
Li MH; Xie Y; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Hu LP; Hua WH; Song SJ; Zhang SF; Cheng J; Xu DZ
World J Hepatol; 2016 May; 8(15):637-43. PubMed ID: 27239256
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
8. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
Chen GY; Zhu MF; Zheng DL; Bao YT; Wang J; Zhou X; Lou GQ
World J Gastroenterol; 2014 Jul; 20(25):8195-200. PubMed ID: 25009392
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
12. Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.
Zeng QL; Yu ZJ; Shang J; Xu GH; Sun CY; Liu N; Li CX; Lv J; Liu YM; Liang HX; Li ZQ; Pan YJ; Hu QY; Li W; Zhang DW; Wang FS
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa208. PubMed ID: 32626791
[TBL] [Abstract][Full Text] [Related]
13. Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers.
Li H; Lin X; Liu L; Qin L; Zheng Y; Liu X; Wei X; Liang S; Liu Y; Zhang J; Chen X; Cao Z
Front Immunol; 2022; 13():864354. PubMed ID: 35529845
[TBL] [Abstract][Full Text] [Related]
14. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
15. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
16. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
17. Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon.
Li H; Liang S; Liu L; Zhou D; Liu Y; Zhang Y; Chen X; Zhang J; Cao Z
Front Immunol; 2022; 13():1091786. PubMed ID: 36618361
[TBL] [Abstract][Full Text] [Related]
18. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B Surface Antigen Seroconversion by Interferon-
Li S; Luo S; Lei Q; Meng Z
Viral Immunol; 2020 Mar; 33(2):122-125. PubMed ID: 31880508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
